Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC trimmed its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 98.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 449 shares of the specialty pharmaceutical company's stock after selling 24,559 shares during the quarter. Cubist Systematic Strategies LLC's holdings in Jazz Pharmaceuticals were worth $55,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Fuller & Thaler Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $59,668,000. Dimensional Fund Advisors LP lifted its stake in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after buying an additional 315,608 shares during the last quarter. Finally, GMT Capital Corp lifted its stake in Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock valued at $62,659,000 after buying an additional 296,800 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Truist Financial raised their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Barclays reissued an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $182.79.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 9th. The shares were purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the acquisition, the director now owns 100,000 shares of the company's stock, valued at $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 28,236 shares of company stock worth $3,956,190 over the last three months. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded up $0.25 during mid-day trading on Friday, reaching $108.07. The stock had a trading volume of 958,795 shares, compared to its average volume of 851,979. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The business has a 50 day simple moving average of $112.87 and a 200 day simple moving average of $121.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the previous year, the business earned $2.68 EPS. Jazz Pharmaceuticals's revenue for the quarter was down .5% on a year-over-year basis. On average, analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.